Dual therapy with allicin and metformin provides superior cardioprotection against doxorubicin-induced cardiotoxicity in rats compared to monotherapy

Metformin and allicin each conferred significant cardioprotection against doxorubicin-induced cardiotoxicity, evidenced by the restoration of cardiac enzymes, reduction of oxidative stress, and improvement in myocardial histoarchitecture. Notably, combined therapy produced greater biochemical and structural recovery than either monotherapy, highlighting its enhanced overall cardioprotective efficacy.